3.58

10.95% -0.44

After Hours: 3.50 -0.08 -2.23%

Insight Molecular Diagnostics Inc (IMDX)

Overview News Price History Discussions Forecast

Insight Molecular Diagnostics Inc stock is traded at $3.58, with a volume of 301.74K. It is down -10.95% in the last 24 hours and down -17.13% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Previous Close:

$4.02

Open:

$4.03

24h Volume:

301.74K

Relative Volume:

1.49

Market Cap:

$117.15M

Revenue:

$1.95M

Net Income/Loss:

$-47.84M

P/E Ratio:

-2.4137

EPS:

-1.4832

Net Cash Flow:

$-27.46M

1W Performance:

-12.68%

1M Performance:

-17.13%

6M Performance:

-21.15%

1Y Performance:

+4.07%

1-Day Range:

$3.50

$4.205

1-Week Range:

$3.50

$4.24

52-Week Range:

$2.42

$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name

Insight Molecular Diagnostics Inc

Sector

Healthcare (1066)

Industry

Diagnostics & Research (50)

Phone

949-409-7600

Address

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, NTRA, IQV, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMDX Insight Molecular Diagnostics Inc	3.58	137.44M	1.95M	-47.84M	-27.46M	-1.4832
TMO Thermo Fisher Scientific Inc	648.43	225.48B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	208.36	140.70B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	345.34	47.41B	2.50B	-226.32M	71.51M	-1.6412
IQV Iqvia Holdings Inc	268.82	43.09B	16.63B	1.39B	2.12B	8.0674
A Agilent Technologies Inc	153.69	41.42B	7.23B	1.41B	1.09B	4.979

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

Insight Molecular Diagnostics Inc Stock (IMDX) Latest News

Sep 11, 2026

Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com

Sep 11, 2026

Sep 08, 2026

Medicare policy boosts iMDx transplant testing frequency - scanx.trade

Sep 08, 2026

Sep 04, 2026